- Population-scale profiling: Helix will support the generation of molecular data from approximately one million biospecimens as part of Precure’s large-scale multi-omics initiative.
- Integrated molecular and clinical data: Clinical whole-genome sequencing and research-grade proteomics will be linked with longitudinal clinical information and advanced computational infrastructure.
- Biobanking implications: The initiative illustrates how large biospecimen collections are increasingly being transformed into integrated molecular-data resources, placing greater emphasis on specimen quality, metadata and sample-to-data linkage.
Precure, LLC has selected Helix as its multi-omics laboratory and AI tools provider for an initiative that plans to generate comprehensive molecular data from approximately one million biospecimens.
According to the Mayo Clinic announcement, Helix will provide clinical whole-genome sequencing (WGS), research-grade proteomic analysis, data infrastructure and AI tools intended to support both biomarker research and the integration of genomic information into clinical care.
The agreement follows the launch of Precure just days earlier by Mayo Clinic and founding partner Thermo Fisher Scientific. The Mayo Clinic-controlled company is being developed to integrate population-scale molecular data with de-identified longitudinal clinical information to support research into the biological changes that occur before disease becomes clinically apparent.
One Million Biospecimens to Support Multi-Omics Data Generation
The scale of the initiative makes the underlying biospecimen resource particularly relevant to biobanking.
Mayo Clinic’s original Precure launch announcement describes plans to generate genomic and proteomic data from one million biospecimens and combine those molecular measurements with longitudinal clinical information collected over several years.
Helix will contribute clinical WGS and what the organizations describe as research-grade proteome sequencing. The companies have also selected Ultima Genomics’ UG200 Ultra Sequencing Platform for large-scale genomic sequencing and sequencing-based proteomic readout.
Thermo Fisher Scientific, meanwhile, is contributing proteomics technologies to the broader Precure ecosystem, including Olink Explore HT and Orbitrap mass spectrometry.
The result is intended to be substantially more than a large collection of molecular measurements. Precure is designed to connect those measurements to longitudinal clinical information, allowing researchers to investigate how molecular patterns change as people move from health toward disease.
From Biospecimens to an Integrated Data Resource
Mayo Clinic’s broader Precure Research initiative is designed around the integration of biological specimens with health information, genetics, environmental data and advanced analytical technologies.
That model reflects a wider evolution in biobanking: the scientific value of a biospecimen increasingly depends not only on its physical preservation but also on the depth, quality and interoperability of the data associated with it.
A blood or tissue specimen, for example, can support increasingly rich layers of genomic, proteomic and other molecular information. When those measurements can be reliably connected with clinical histories and longitudinal outcomes, the resource may support biomarker discovery, patient stratification and disease-progression research that would be difficult to achieve from isolated samples.
Biobanking.com has previously explored this transition in its coverage of the growing role of multi-omics in biobanking, where biospecimen repositories increasingly function as integrated biological and data infrastructures rather than simply long-term sample stores.
Scale Increases the Importance of Pre-Analytical Metadata
Generating molecular data from approximately one million biospecimens also creates substantial operational requirements.
For multi-omics studies, variability introduced during specimen collection, processing, storage and retrieval can affect downstream molecular measurements. At population scale, consistent specimen provenance, pre-analytical metadata, sample identification and quality-control procedures therefore become increasingly important for interpreting whether observed differences reflect biology or technical variation.
The public Precure announcements emphasize that molecular and clinical data will be generated in a highly standardized setting, but they do not currently provide detailed information about the biospecimen types included, collection and storage histories, pre-analytical variables or assay-specific specimen quality criteria.
Those details will be particularly relevant as the resource develops, because the ability to harmonize biospecimen histories with genomic, proteomic and longitudinal clinical data will influence how reliably the dataset can support cross-cohort analyses and biomarker discovery.
Clinical Genomics and Research Proteomics Remain Distinct
The announcement also makes an important distinction between the different molecular outputs being generated.
Helix describes the whole-genome sequencing component as clinical WGS and cites its CLIA/CAP laboratory infrastructure, while the proteomic component is explicitly described as research-grade.
That distinction matters because population-scale multi-omics resources often combine data generated for different intended uses and under different analytical frameworks. Research-grade molecular measurements can be highly valuable for discovery without necessarily being suitable for direct clinical decision-making.
Precure’s longer-term objective is to make molecular information more useful across both research and healthcare, but the current announcement does not establish that all multi-omics outputs will function as clinical tests.
A Shift From Sample Scale to Sample-Data Scale
For the biobanking community, the most notable aspect of the Helix agreement is therefore not simply the selection of another technology provider.
It is the planned transformation of approximately one million biospecimens into an interconnected genomic, proteomic and longitudinal clinical-data resource.
As initiatives of this scale become more common, biobanking infrastructure will increasingly need to support not only specimen preservation and retrieval but also molecular-data generation, metadata harmonization, computing, governance and reliable linkage between physical samples and digital information.
Precure provides a high-profile example of that transition — from measuring the size of a biospecimen collection primarily by the number of samples stored to considering the depth and usability of the biological and clinical information that can be generated from them.
About the Author
Biobanking.com delivers valuable news and information on biobanking, biorepositories, cryopreservation, and biosample/biospecimen management, while connects buyers with top vendors globally.
